1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Drug Pricing

Sandoz Pledges Price Stability Amid Coronavirus

CEO Richard Saynor Discusses Chinese Supply-Chain Pressures

 
• By Dave Wallace

Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.

Covid-19
Sandoz will ensure stable pricing for a basket of coronavirus-related essential drugs • Source: Shutterstock

Sandoz will maintain stable pricing for coronavirus-related essential medicines that it markets, CEO Richard Saynor has pledged, amid ongoing concerns over the potential short-term and longer-term impacts of the outbreak on the supply chain.

More from Drug Pricing

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By Dave Wallace

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

 
• By Dave Wallace

In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.

Sandoz Slams ‘Desperate’ J&J Attempt To Block US Private-Label Stelara Rival

 
• By Dave Wallace

Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”

More from Policy & Regulation

BGMA Hits Back At ABPI Complaints Over UK Pricing Scheme

 
• By Dave Wallace

Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”

Unfreezing US FDA: Generic Drug Officials Make Plea For Public Workshops

 
• By Michael McCaughan

The FDA generic drugs team’s first public workshop of the second Trump Administration ended with a request that industry amplify the value it finds from public engagement.

Regulatory Recap: Proposed FDA Head Makary To Advocate For Generics And Biosimilars

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the globe.